Skip to main content
. 2020 Jul 23;12(8):694. doi: 10.3390/pharmaceutics12080694
API active pharmaceutical ingredient
API–OSILs active pharmaceutical ingredient organic salts and ionic liquids
C16Py cetylpyridinium
C2OHDMIM 1-(2-hydroxyethyl)-2,3-dimethylimidazolium
C2OHMIM 1-(2-hydroxyethyl)-3-methylimidazolium
C3OMIM 1-(2-methoxyethyl)-3-methylimidazolium
Ch choline
Cip ciprofloxacin
CMC critical micelle concentration
EMIM 1-ethyl-3-methylimidazolium
FQ fluoroquinolone
FQ-OSILs fluoroquinolone-based organic salts and ionic liquids
FTIR Fourier-transform infrared spectroscopy
IC50 half maximal inhibitory concentration
IL ionic liquid
NMR nuclear magnetic resonance
Nor norfloxacin
OSIL organic salt and ionic liquid
RDIC50 relative decrease in inhibitory concentration for 50% bacterial growth
RTILsSEM room temperature ionic liquidsstandard error mean
Tg glass transition temperature
Tm melting temperature